ReviewDrug design, development and therapy2026
Advances in Schaftoside Research: Pharmacological Mechanisms, Pharmacokinetics, and Therapeutic Perspectives.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schaftoside is a flavonoid C-glycoside widely existing in medicinal plants and has been extensively reported due to its pharmacological activities, such as anti-inflammatory, hepatoprotective, antioxidant and neuroprotective activities. These pharmacological activities may be attributed to its effects on apoptosis, autophagy, ferroptosis, pyroptosis, oxidative stress and related signaling pathways. In this review, we summarize recent advances in pharmacological activities and pharmacomechanisms of schaftoside as well as its pharmacokinetic properties, formulation strategies, safety and therapeutic application. The biological effects of schaftoside have been demonstrated in various pathological models by relevant in vitro and in vivo experiments. However, its oral bioavailability is extremely low, which is a big challenge for its further development. Some formulation approaches, especially drug delivery systems, have shown preliminary prospects, but related reports are limited. Based on available toxicological findings, schaftoside is expected to have a relatively safe profile. However, the relationship between schaftoside and chemosensitivity as well as drug resistance needs to be further investigated. In conclusion, schaftoside is a promising bioactive compound; however, its pharmacokinetic properties and available clinical evidence need to be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.